Partnerships Provide Global Foundation For Alvotech
Network Of Deals Gives Company’s Biosimilar Portfolio Worldwide Reach
A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.
You may also be interested in...
Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.
Alvotech has launched a US legal challenge over intellectual property around AbbVie’s Humira, claiming that the company enjoys a “wrongful monopoly” on the top-selling arthritis treatment for which the biosimilars company is developing a high-concentration adalimumab rival.
Alvotech has issued a robust rebuttal of accusations that it obtained AbbVie trade secrets relating to Humira for use in developing its biosimilar adalimumab rival.